Name Surname:
Serkan Akın
Title:
Assoc.Prof.Md.
Department:
Medical Oncology
Contact:
(312) 305 29 29
1981 yılında Simav’da doğdu. Bursa Fen Lisesi’nden 1999’da mezun oldu. İstanbul Bilim Üniversitesi Tıp Fakültesi’ni tam burslu olarak 2006’da bitirdi. 2011 yılında Hacettepe Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı’nda İç Hastalıkları uzmanlık eğitimini tamamladı. Hacettepe Üniversitesi Medikal Onkoloji Bilim Dalı’nda yandal eğitimini tamamlayarak 2016 yılında Tıbbi Onkoloji uzmanı oldu. 2015’de ve 2016’da Tıbbi Onkoloji Kongresi’nde en iyi çalışma ve en iyi sözel bildiri ödülü aldı. Rize’de Devlet Hizmet Yükümlülüğünü yaptı.
Akin S, Dizdar O, Karakas Y, Turker A, Kars A. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma. Curr Probl Cancer. 2018 May - Jun;42(3):344-349. doi: 10.1016/j.currproblcancer.2018.01.011. Epub 2018 Jan 31.
Akın Ş, Yazgan Aksoy D, Akın S, Kılıç M, Yetişir F, Bayraktar M. Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma. Turk J Med Sci. 2017 Dec 19;47(6):1723-1727. doi: 10.3906/sag-1702-99.
Akın S, Akın Ş, Gedik E, Haznedaroğlu E, Doğan AL, Altundağ MK. Serum Chemerin Level in Breast Cancer. UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi, Doi: 10.4999/uhod.171847, 2017.
Akın S, Dizdar Ö, Özışık L, Durusu Tanrıöver M, Kamışlı S, Erman M, Hayran MK. Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy. UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi, Doi: 10.4999/uhod.161317, 2016.
Karakas Y, Akin S, Dizdar O, Aksoy S. Analysis of the Adjuvant Hormone Therapy Randomized Trial. J Clin Oncol. 2016 Jun 10;34(17):2070. doi: 10.1200/JCO.2015.65.4277. Epub 2016 Mar 21.
Ates O, Babacan T, Kertmen N, Sarici F, Cenoli A, Akin S, Karakas Y, Kilickap S, Ozisik Y, Sever AR, Aksoy S, Altundag K. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. J BUON. 2016 Mar-Apr;21(2):375-81.
Karatas F, Sahin S, Babacan T, Akin S, Sever AR, Altundag K. Leg cramps associated with tamoxifen use--possible mechanism and treatment recommendations. J BUON. 2016 Mar-Apr;21(2):520.
Dizdar O, Akin S, Hayran M. Interpretation of survival data: which graphical analysis is appropriate? Ther Adv Med Oncol. 2016 Jul;8(4):312. doi: 10.1177/1758834016644870. Epub 2016 May 22.
Ozen M, Gunduz M, Ates O, Babacan T, Sever AR, Akin S, Ozisik Y, Altundag K. Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients. J BUON. 2016 Jul-Aug;21(4):799-808.
Dizdar O, Bilgin E, Akin S, Kilickap S, Hayran M. Evaluation of complementary and alternative medicine trials registered in clinicaltrials.gov database. J BUON. 2017 Mar-Apr;22(2):530-534.
Akin S, Dizdar O, Hayran MK (2015). Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Letter to Editor. ANNALS OF SURGICAL ONCOLOGY.
Serefhanoglu S, Buyukasik Y, Goker H, Akin SC, Akin S, Sayinalp N, Haznedaroglu IC, Ozcebe OI. Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature. Med Oncol. 2010 Mar;27(1):55-8.
Akin S, Akin S, Karadag O, Kalyoncu U, Balcı S, Ozgen B. Nasopharyngeal sarcoidosis: a rare involvement. Rheumatol Int. 2012 May; 32(5):1407-9.
Akin S, Babacan T, Sarici F, Altundag K. A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors. J BUON. 2014 Jan-Mar;19(1):42-6. Review.
Gul G, Babacan T, Akin S, Sarici F, Altundag K. Breast sarcoma: a rare malignancy. J BUON. 2014 Apr-Jun;19(2):577
Guven DC, Babacan T, Sarici F, Akin S, Altundag K, Turker A. Acute erythroid leukemia in a patient with chronic lymphocytic leukemia. J BUON. 2014 Oct-Dec;19(4):1127.
Kertmen N, Aksoy S, Uner A, Sargon M, Ozkayar O, Keskin O, Babacan T, Sarici F, Sendur MA, Arik Z, Akin S, Altundag K. Which sequence best protects the heart against trastuzumab and anthracycline toxicity? An electron microscopy study in rats. Anticancer Res. 2015 Feb;35(2):857-64.
Kertmen N, Babacan T, Keskin O, Solak M, Sarici F, Akin S, Arik Z, Aslan A, Ates O, Aksoy S, Ozisik Y, Altundag K. Molecular subtypes in patients with inflammatory breast cancer; a single center experience. J BUON. 2015 Jan-Feb;20(1):35-9.
Ates O, Sunar V, Babacan T, Akin S, Kertmen N, Altundag K. Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab. J BUON. 2015 Jan-Feb;20(1):349.
Babacan T, Efe O, Hasirci AS, Demirci F, Buyukhatipoglu H, Balakan O, Sarici F, Kertmen N, Esin E, Akin S, Ates O, Aksoy S, Sever AR, Altundag K. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori. 2015 Jul-Aug;101(4):418-23.
Hacioglu B, Akin S, Sever AR, Altundag K. Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients. Future Oncol. 2015 Sep;11(18):2495-7. doi: 10.2217/fon.15.164. Epub 2015 Aug 17.
Hacioglu B, Akin S, Babacan T, Sever AR, Altundag K. How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission? Future Oncol. 2015;11(20):2799-801. doi: 10.2217/fon.15.165. Epub 2015 Sep 7.
Germ hücreli tümörler (testis), sarkomlar ve hematolojik tümörler
| High School |
|
|||||||||
| Univercity |
|
|||||||||
| Academic Background |
|
|||||||||
| Foreign Language | İngilizce |
: (312) 305 29 29
: drserkanakin@gmail.com